GSK (LON:GSK – Get Free Report) had its price objective increased by research analysts at Barclays from GBX 1,450 ($18.15) to GBX 1,575 ($19.71) in a report issued on Monday, FlyOnTheWall reports. Barclays‘s price objective points to a potential upside of 4.43% from the stock’s current price.
Several other equities research analysts have also issued reports on the stock. Shore Capital reissued a “buy” rating on shares of GSK in a report on Friday, June 16th. Bank of America dropped their price objective on shares of GSK from GBX 1,450 ($18.15) to GBX 1,390 ($17.39) in a research note on Monday, July 17th. Berenberg Bank restated a “buy” rating and issued a GBX 1,730 ($21.65) price objective on shares of GSK in a research note on Friday, July 28th. Jefferies Financial Group restated a “hold” rating and issued a GBX 1,575 ($19.71) price objective on shares of GSK in a research note on Monday, June 26th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a GBX 1,700 ($21.27) price objective on shares of GSK in a research note on Tuesday, September 5th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of GBX 1,572.50 ($19.68).
GSK Stock Performance
Insiders Place Their Bets
In related news, insider Jonathan Symonds acquired 6,000 shares of the firm’s stock in a transaction on Friday, June 23rd. The shares were purchased at an average price of GBX 1,440 ($18.02) per share, with a total value of £86,400 ($108,121.64). In other GSK news, insider Hal Barron sold 19,446 shares of the company’s stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of GBX 3,462 ($43.32), for a total transaction of £673,220.52 ($842,473.43). Also, insider Jonathan Symonds bought 6,000 shares of GSK stock in a transaction dated Friday, June 23rd. The stock was acquired at an average cost of GBX 1,440 ($18.02) per share, for a total transaction of £86,400 ($108,121.64). Insiders have purchased a total of 6,018 shares of company stock valued at $8,664,147 in the last 90 days. 1.74% of the stock is currently owned by insiders.
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
- Five stocks we like better than GSK
- Golden Cross Stocks: Pattern, Examples and Charts
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- Best Stocks Under $5.00
- 5 Reasons Mullen Automotive is About to Turn a Corner
- Business Services Stocks Investing
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.